For decades, diabetes care has focused on treating symptoms, rather than addressing the core therapeutic targets.

Biomolecular LLC is changing this!

A functional neurophysiologic restoration for Type 2 Diabetes is possible through Non-Invasive, AI-powered electroceuticals.

Our AI-driven Neurophysiologic Electromagnetic Stimulation (nEMS) Device is the Gateway to Durable Diabetes Remission.

Traditional therapy primarily addresses inadequate insulin secretion by administering exogenous insulin. This often culminates in uncontrolled T2DM with irreversible complications. Impaired insulin secretion is a neurophysiology problem upstream of the pancreatic beta(β) cell’s calcium ion (Ca2+) channel signaling. The sympathetic nervous system (SNS) supplies the islets of Langerhans and the liver via the splanchnic nerves. The SNS is the master controller of glucose metabolism. SNS is hyperactivated under chronic stressors, slowing down non-essential processes, such as digestion. Chronic SNS hyperactivation underlies neurophysiologic impairment in T2DM. Our patented nEMS device targets the upstream SNS for neurostimulation, restoring ionic channel function in pancreatic β-cells to achieve durable insulin secretion.

Technology

Neurophysiologic Electromagnetic Stimulation (nEMS)

Therapy AI-Driven Innovation for Restoring Insulin Secretion

Biomolecular LLC has developed a patented therapeutic platform that combines artificial intelligence with neurophysiologic electromagnetic stimulation (nEMS) to restore pancreatic β-cell function. This non-invasive approach offers a transformative alternative to traditional drug-based diabetes treatments.

How It Works

Our nEMS therapy uses targeted electromagnetic pulses to stimulate neurophysiologic pathways that regulate pancreatic function. AI algorithms personalize stimulation protocols based on patient-specific data, optimizing therapeutic outcomes and minimizing side effects.

Key Features:

Non-invasive and drug-free
AI-guided treatment personalization
Restores natural insulin secretion
Targets both Type 1 and Type 2 diabetes mechanisms

Scientific Foundation

Our technology is built on decades of research in electrophysiology, biomedical engineering, and artificial intelligence. Inspired by pioneers like Luigi Galvani and Robert Bárány, we apply classical bioelectric principles to modern therapeutic design.

Scientific Pillars:

Electrophysiologic modulation of β-cell activity
Machine learning for adaptive therapy control
Bioelectronic device engineering and sensor integration

Development Status

Market-ready prototype completed
Preclinical validation underway
Seeking federal funding for clinical trials and regulatory approval
Aligned with NIH, NSF, and DoD research priorities

Data adapted from U.S. Patent No. 8,457,745 – Method for Pancreatic β-cell Control (https://patents.google.com/patent/US8457745B1/en)

We’re actively seeking FDA approval to proceed to a clinical trial. Biomolecular LLC is further advancing its patented nEMS device by integrating it with an AI algorithm for precise anatomical placement of stimulating electrodes.

AI-driven nEMS Technology

We’re seeking to future-proof our novel therapeutic Device with AI integration.

How It Works

Our nEMS therapy uses targeted electromagnetic pulses to stimulate neurophysiologic pathways that restore the neurophysiologic function of pancreatic beta cells.

The restored function of β cells’ calcium ion (Ca2+)channels provides functional restoration of insulin secretion.

AI algorithms personalize stimulation protocols based on patient-specific data, optimizing therapeutic outcomes and therapy adaptation.

Key Features:

Non-invasive therapy
Dual targeting of neurophysiologic impairment of both Type 1 and Type 2 diabetes
Restores natural insulin secretion, eliminating the need for insulin therapy
AI-guided treatment precision, personalization and therapy adaptation

Scientific Foundation

Our AI-driven nEMS technology is built on decades of research in electrophysiology, biomedical engineering, and artificial intelligence. Inspired by pioneers like Luigi Galvani and Robert Bárány, we apply classical bioelectric principles to modern therapeutic design.

Our Scientific Pillars:

Electrophysiologic modulation of β-cell activity
Machine learning for adaptive therapy control
Bioelectronic device engineering and sensor integration

Development Status

Market-ready prototype completed
Preclinical validation underway
Seeking federal funding for clinical trials and regulatory approval
Aligned with NIH, NSF, and DoD research priorities

"THE GLOBAL DIABETES CRISIS: ECONOMIC & HUMAN IMPACT"

Global cost of diabetes set to double by 2030

Diabetes mellitus represents one of the most significant and rapidly growing challenges to global health in the 21st century. Beyond its profound impact on individual well-being and public health systems, the disease carries a substantial and increasing economic cost that threatens to strain national economies worldwide. A comprehensive 2018 study published in Diabetes Care provides a critical forecast of this financial impact, projecting the global economic burden of diabetes in adults through the year 2030.

The research, conducted by Bommer et al. (2018), modeled the economic consequences of the disease across 180 countries, considering various scenarios for its progression. The findings reveal a stark trajectory. In 2015, the absolute global economic burden of diabetes was estimated at U.S. $1.3 trillion. By 2030, this figure is projected to increase dramatically, reaching between $2.1 trillion and $2.5 trillion, depending on the effectiveness of global health interventions.

To understand the full scope of the issue, the study analyzed three potential futures:

A Baseline Scenario, where the increase is driven only by population aging and urbanization, projects costs will rise to $2.2 trillion.
A Past Trends Scenario, assuming the disease continues to spread at its historical rate, forecasts the highest costs at $2.5 trillion.
A Target Scenario, which assumes that global targets under the Sustainable Development Goals (SDG) and World Health Organization (WHO) plans are met, still projects a substantial cost of $2.1 trillion.

This translates to a significant portion of the world's economic output. The study found that the costs of diabetes as a share of global GDP are expected to rise from 1.8% in 2015 to a high of 2.2% by 2030 (Bommer et al., 2018).

The most sobering conclusion from the analysis is that even if countries successfully meet international targets for disease prevention and control, the overall global economic burden is not expected to decrease. This highlights the urgent need for policymakers to take decisive action to prepare and strengthen health and social security systems to mitigate the severe and escalating economic consequences of diabetes.

Find out more https://doi.org/10.2337/dc17-1962

Biomolecular LLC

Translating Electromagnetic Signals into Non-Invasive Therapeutics

Technology

Neurophysiologic Electromagnetic Stimulation (nEMS)

Based on Paradigm-Shifting Pre-clinical data

"THE GLOBAL DIABETES CRISIS: ECONOMIC & HUMAN IMPACT"

Global cost of diabetes set to double by 2030

mission statement

Contact Information

Biomolecular LLC — Translating Electromagnetic Signals into Non-Invasive Therapeutics

Biomolecular LLC

Hours